Adjuvant Paclitaxel and Trastuzumab for Node-Negative, HER2-Positive Breast Cancer

BACKGROUND: No single standard treatment exists for patients with small, node-negative, human epidermal growth factor receptor type 2 (HER2)–positive breast cancers, because most of these patients have been ineligible for the pivotal trials of adjuvant trastuzumab. METHODS: We performed an uncontrol...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:N Engl J Med
Autors principals: Tolaney, Sara M., Barry, William T., Dang, Chau T., Yardley, Denise A., Moy, Beverly, Marcom, P. Kelly, Albain, Kathy S., Rugo, Hope S., Ellis, Matthew, Shapira, Iuliana, Wolff, Antonio C., Carey, Lisa A., Overmoyer, Beth A., Partridge, Ann H., Guo, Hao, Hudis, Clifford A., Krop, Ian E., Burstein, Harold J., Winer, Eric P.
Format: Artigo
Idioma:Inglês
Publicat: 2015
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4313867/
https://ncbi.nlm.nih.gov/pubmed/25564897
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1406281
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars